This bill amends the Harmonized Tariff Schedule to establish specific classifications for silicone prosthetics and mastectomy bras for breast cancer survivors.
Carol Miller
Representative
WV-1
This bill amends the Harmonized Tariff Schedule of the United States to establish new classification subheadings for silicone prosthetics and mastectomy bras. These changes, effective January 1, 2027, are designed to specifically categorize these essential items for breast cancer survivors.
This bill updates the Harmonized Tariff Schedule (HTS)—the massive rulebook the U.S. uses to tax imported goods—to create specific categories for silicone prosthetics and mastectomy bras. Starting at 12:01 a.m. on January 1, 2027, these items will no longer be lumped into general categories but will instead have their own dedicated subheadings (3926.20.61 for prosthetics and 9021.10.60 for bras). By carving out these specific slots in the tax code, the government is setting the stage to potentially lower or eliminate the import duties that usually drive up the price of these essential medical supplies.
Right now, when a company imports medical supplies, they are often classified under broad categories that might carry higher tax rates. Sections 1 and 2 of this bill change that by giving these specific products their own identity in Chapters 39 and 90 of the HTS. For someone managing a specialty medical boutique or a survivor shopping for a replacement prosthetic, this technical change is the first step toward lower shelf prices. By separating a mastectomy bra from a standard garment, the law allows for targeted tax relief that doesn't have to apply to the entire clothing industry.
While the bill is clear about what is being classified, it’s also specific about when. The January 1, 2027, start date gives the customs department and manufacturers a long runway to update their paperwork and logistics systems. For a patient currently paying out-of-pocket for these items, the impact isn't immediate, but it creates a permanent structural change in how the U.S. treats post-mastectomy care products. It’s a move that treats these items more like essential medical devices and less like general consumer goods, which could lead to more stable pricing and better availability down the road.